↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Argenx adds anti-CD122 antibody FB102 via Forte tender, layering second autoimmune mechanism onto **$12B** FcRn franchise at modest cost.
$12 billion
market capitalization autoimmune franchise
$22 million
in cash on the balance sheet as of Q2…
$18 million
annually and limited competitive tension
30 to 45 days
from commencement—will reveal whether argenx negotiated a go-shop or…
Argenx SE has commenced a tender offer to acquire Forte Biosciences, Inc., the clinical-stage biopharmaceutical company advancing FB102, a proprietary anti-CD122 monoclonal antibody. The move adds a second mechanism—complementary to argenx's FcRn-blocking platform—into what is already a $12 billion market capitalization autoimmune franchise.
Forte's FB102 targets CD122, the beta subunit of the IL-2 and IL-15 receptor complex, implicating pathways distinct from argenx's flagship Vyvgart (efgartigimod). The asset has completed Phase 1 safety studies and is positioned for expansion into moderate-to-severe atopic dermatitis and potentially alopecia areata. Forte's enterprise value at last close was approximately $48 million, with $22 million in cash on the balance sheet as of Q2 2025. The tender represents a modest bolt-on acquisition in absolute terms, but the strategic aperture is wider—argenx is now building a dual-pronged immunology toolkit that can be layered or sequenced in IL-2/IL-15-driven indications.
The significance is in the optionality. Efgartigimod works by degrading pathogenic IgG; FB102 interrupts T-cell and NK-cell signaling upstream. For myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and pemphigus, argenx already holds FDA approvals or late-stage readouts. Adding CD122 blockade opens a second vector into T-cell-mediated dermatology and potentially solid-organ transplant rejection, where IL-15 biology is implicated. The company is not disclosing deal consideration in the initial tender filing, but given Forte's run-rate burn of roughly $18 million annually and limited competitive tension, the headline multiple is likely modest—1.5x to 2.5x book, or $70 million to $120 million all-in. For argenx, that is less than two quarters of R&D spend and preserves optionality on a mechanism that pairs cleanly with its existing sales force and KOL network in neurology and dermatology.
Allocators should track three events. First, the tender acceptance threshold and close timeline—likely 30 to 45 days from commencement—will reveal whether argenx negotiated a go-shop or no-shop period and whether competing bids emerge from dermatology-focused acquirers like Incyte or Galderma. Second, any disclosure of combination trial plans pairing FB102 with efgartigimod in autoimmune dermatoses would signal accelerated capital deployment and validate the dual-mechanism thesis. Third, argenx's next quarterly call—expected mid-November 2025—will clarify whether this tender is the opening move in a broader tuck-in M&A campaign or a one-off opportunistic buy.
The tender is live. Forte's board has not yet filed a formal recommendation, which means argenx either has a pre-negotiated support agreement or is moving hostile. Given Forte's cash position and lack of near-term catalysts, the former is more probable. The clock on acceptance runs through early September.
Branded by POPS4 · proof in 60 seconds
For the principal
Track acceptance timeline through early September; modest outlay preserves optionality on dual-mechanism autoimmune strategy without balance-sheet stress.
For the operator
Watch for combination trial disclosure and competing bids from Incyte or Galderma; Forte's $48M enterprise value suggests clean bolt-on, not defensive premium.
For the house
No position; monitor Q3 call for broader tuck-in M&A signals; CD122 mechanism diversifies immunology exposure if efgartigimod reimbursement compresses.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.